产品
编 号：F618442
分子式：C29H25FN4O5
分子量：528.53
分子式：C29H25FN4O5
分子量：528.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2367004-54-2
产品详情
生物活性：
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research.
体内研究：
Zanzalintinib (10 mg/kg/天；口服；持续 14 天) 在异种移植研究中引起显著的肿瘤生长抑制。Zanzalintinib 对 p-MET 和 p-VEGFR2 的抑制率分别为 82% 和 96%。Zanzalintinib (化合物 8；3 mg/kg；iv) 的 T1/2 为 5.4 小时，CL 为 43 mL/hr·kg。Zanzalintinib (3 mg/kg；口服) 对大鼠的 T1/2 为 7.1 小时，Cmax 为 11.4 μM。Animal Model:Rat
Dosage:3 mg/kg (Pharmacokinetic Analysis)
Administration:IV
Result:Had a T1/2 of 5.4 hours, a CL of 43 mL/hr?kg.
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research.
体内研究：
Zanzalintinib (10 mg/kg/天；口服；持续 14 天) 在异种移植研究中引起显著的肿瘤生长抑制。Zanzalintinib 对 p-MET 和 p-VEGFR2 的抑制率分别为 82% 和 96%。Zanzalintinib (化合物 8；3 mg/kg；iv) 的 T1/2 为 5.4 小时，CL 为 43 mL/hr·kg。Zanzalintinib (3 mg/kg；口服) 对大鼠的 T1/2 为 7.1 小时，Cmax 为 11.4 μM。Animal Model:Rat
Dosage:3 mg/kg (Pharmacokinetic Analysis)
Administration:IV
Result:Had a T1/2 of 5.4 hours, a CL of 43 mL/hr?kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备